Sponsored By

January 31, 2013

1 Min Read
Myo-inositol Reduces Gestational Diabetes Risk

MESSINA, ItalyMyo-inositol supplementation may reduce the risk of gestational diabetes mellitus (GMD) in pregnant women, according to a study published in Diabetes Care.

For the two-year, randomized, placebo-controlled trial, researchers at the University of Messina, Italy, studied 220 pregnant women with one parent with type 2 diabetes (Diabetes Care. 2013 Jan 22.). At the end of their first trimester, the women began treatment with either 2g myo-inositol plus 200 µg folic acid twice a day or 200 µg folic acid twice daily. Scientists measured the incidence of GDM, in addition to fetal macrosomia, gestational hypertension, preterm deliver and caesarean section.

Six percent of the myo-inositol group were diagnosed with GDM, compared to the placebo group's 15.3 percent. Scientists also noted a reduction in GDM risk, fetal macrosomia (high birth weight) and average fetal weight at delivery, which can cause delivery complications.

This new finding  complements recent University of Pittsburgh research on healthy birth weights. Published in the Journal of Clinical Endocrinology & Metabolism, the study found mothers with higher levels of vitamin D were more likely to deliver healthy weight babies.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like